2016
Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis
Fung L, Mahajan R, Nozzolillo A, Bernal P, Krasner A, Jo B, Coury D, Whitaker A, Veenstra-Vanderweele J, Hardan A. Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis. Pediatrics 2016, 137: s124-s135. PMID: 26908468, DOI: 10.1542/peds.2015-2851k.Peer-Reviewed Original ResearchConceptsPharmacologic treatmentSide effectsPrimary study outcome measureAutism spectrum disorderPlacebo-controlled RCTsExtrapyramidal side effectsStudy outcome measuresEnd of treatmentRisk of biasParallel group designYouth ages 2Potential side effectsPublic health issueDetails of interventionsEffect sizeMedication groupAdverse reactionsSevere irritabilityOutcome measuresSignificant efficacyLarge effect sizesMeta-AnalysisSystematic reviewStudy participantsWeight gain
2015
ADHD Symptoms in a Non-Referred Low Birthweight/Preterm Cohort: Longitudinal Profiles, Outcomes, and Associated Features
Krasner AJ, Turner JB, Feldman JF, Silberman AE, Fisher PW, Workman CC, Posner JE, Greenhill LL, Lorenz JM, Shaffer D, Whitaker AH. ADHD Symptoms in a Non-Referred Low Birthweight/Preterm Cohort: Longitudinal Profiles, Outcomes, and Associated Features. Journal Of Attention Disorders 2015, 22: 827-838. PMID: 26700791, PMCID: PMC4919227, DOI: 10.1177/1087054715617532.Peer-Reviewed Original ResearchConceptsClinical featuresPreterm birth cohortHigh-risk cohortPreterm cohortFunctional outcomePositive screenPsychiatric disordersBirth cohortADHD evaluationSymptom trajectoriesMotor problemsHyperactive-impulsive symptomsCohortPoor functioningLatent class analysisAssociated featuresStudy objectivePossible ADHDSchool ageAutism spectrum disorderDisordersOutcomesSpectrum disorderADHDClass analysis
2013
Being with the patient: the use of "clinical evidence," reconsidered.
Harper G, Becker DF, Copans SA, Flaherty LT, Ghalib K, Krasner AJ, Kwok S, Onesti SJ, Wittenberg J. Being with the patient: the use of "clinical evidence," reconsidered. The Journal Of Nervous And Mental Disease 2013, 201: 813-7. PMID: 23995038, DOI: 10.1097/NMD.0b013e3182a2142f.Peer-Reviewed Original Research
2007
DTNBP1 (Dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3' end of the gene.
Duan J, Martinez M, Sanders AR, Hou C, Burrell GJ, Krasner AJ, Schwartz DB, Gejman PV. DTNBP1 (Dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3' end of the gene. Human Heredity 2007, 64: 97-106. PMID: 17476109, PMCID: PMC2861529, DOI: 10.1159/000101961.Peer-Reviewed Original Research
2005
Neuregulin 1 (NRG1 ) and schizophrenia: analysis of a US family sample and the evidence in the balance.
Duan J, Martinez M, Sanders AR, Hou C, Krasner AJ, Schwartz DB, Gejman PV. Neuregulin 1 (NRG1 ) and schizophrenia: analysis of a US family sample and the evidence in the balance. Psychological Medicine 2005, 35: 1599-610. PMID: 16219118, DOI: 10.1017/S0033291705005428.Peer-Reviewed Original Research